Guangdong Taienkang Pharmaceutical Valuation

Q: What is the Fair Price of 301263 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

301263 (CN¥14.3) is trading above our estimate of [[fair value]] (CN¥13.47)

Is 301263 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301263 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301263 (CN¥14.3) is trading above our estimate of fair value (CN¥13.47)

Significantly Below Fair Value: 301263 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301263?

Key metric: As 301263 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301263. This is calculated by dividing 301263's market cap by their current earnings.
What is 301263's PE Ratio?
PE Ratio	45x
Earnings	CN¥134.71m
Market Cap	CN¥5.95b

301263 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	7.5x
Enterprise Value/EBITDA	28.4x
PEG Ratio	1.2x

Price to Earnings Ratio vs Peers

How does 301263's PE Ratio compare to its peers?

The above table shows the PE ratio for 301263 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	28.3x
000915 Shandong Wit Dyne HealthLtd	12.5x	16.5%	CN¥6.0b
688513 Chengdu Easton Biopharmaceuticals	24.1x	23.5%	CN¥6.0b
300194 Fuan Pharmaceutical (Group)	21x	n/a	CN¥5.8b
301211 Hubei Biocause Heilen Pharmaceutical	55.6x	n/a	CN¥5.9b
301263 Guangdong Taienkang Pharmaceutical	45x	37.7%	CN¥6.0b

Price-To-Earnings vs Peers: 301263 is expensive based on its Price-To-Earnings Ratio (45x) compared to the peer average (28.3x).

Price to Earnings Ratio vs Industry

How does 301263's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 301263 is expensive based on its Price-To-Earnings Ratio (45x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 301263's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301263 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	45x
Fair PE Ratio	32.4x

Price-To-Earnings vs Fair Ratio: 301263 is expensive based on its Price-To-Earnings Ratio (45x) compared to the estimated Fair Price-To-Earnings Ratio (32.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

-3.9%

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

-2.0%

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

-1.2%

18.8%